PURPOSE. Loss or dysfunction of trabecular meshwork (TM) cells has been associated with the development of pathologically elevated IOP, and it is conceivable that replacement of damaged TM cells could restore function to the TM. We propose that the use of TM-like cells derived from induced pluripotent stem cells (iPSCs) created from a patient's own dermal fibroblasts offers the best solution to this challenge. Here we demonstrate that mouse iPSCs can be induced to differentiate into TM-like cells suitable for autologous transplantation.
G laucoma is a leading cause of irreversible blindness worldwide. 1 The development of this disease is frequently accompanied by an increase in intraocular pressure (IOP) that can lead to visual field loss and blindness as a result of ganglion cell death and optic nerve atrophy. [2] [3] [4] The aqueous humor inside the eye is continuously produced, and the majority of the fluid exits through the trabecular meshwork (TM). 5 Trabecular meshwork outflow pathways are critical in providing resistance to aqueous humor outflow and in maintaining IOP in the healthy eye. [6] [7] [8] The precise etiology of the elevated IOP in primary openangle glaucoma (POAG) is still unknown, but numerous studies point to an outflow obstruction of the intraocular fluid within the TM or the endothelial lining of Schlemm's canal. 9, 10 Cellularity is decreased in the TM of POAG patients, [11] [12] [13] [14] [15] and it is likely that TM cells become dysfunctional prior to death and increasingly fail to carry out their physiological roles, leading to enhanced aqueous humor outflow resistance and the development of pathologically elevated IOP. [16] [17] [18] It is conceivable that replacement of damaged or lost TM cells could restore function to the TM and re-establish IOP control. Data have shown that laser trabeculoplasty causes division of early TM cells and that these cells migrate and repopulate the burn sites. The observed increase in outflow facility and decrease in IOP in POAG patients may be due to the activity of these newly created cells either through direct interaction with the extracellular matrix of the TM or through a paracrine effect on the remaining endogenous cells. [19] [20] [21] Alternatively, it may be possible to achieve the same effect using an endogenously supplied cell population. The use of stem or progenitor cells for the purpose of cellular replacement is promising because of their demonstrated ability to induce tissue reconstruction and functional regeneration. 22, 23 Pluripotent cells can be obtained from many tissues of early embryos or adults. Several groups have successfully isolated TM progenitor cell populations from free-floating neurospheres derived from human TM cells, TM insert cells, or human TM as side populations or clones. [24] [25] [26] Cells derived through these approaches closely resemble primary TM cells, but harvesting tissue to obtain a sufficient number of such cells is not feasible from a living eye. In order to develop transplantation of TM cells as a clinically viable treatment approach for POAG, we believe that harvesting of donor cells must be reliable, must be minimally invasive, and must yield a significant number of cells. Furthermore, autologous transfer to avoid immune responses and ethical concerns associated with the use of embryonic stem cells would be desirable. One approach that can overcome these hurdles is the use of induced pluripotent stem cells (iPSCs). Induced PSCs are generated via genetic reprogramming of adult somatic cells to pluripotency through simultaneous expression of four transcription factors: Oct4, Sox2, Klf4, and c-Myc. 27 Ultimately, the use of TM-like cells derived from iPSCs created from a patient's own dermal fibroblasts may offer the best solution to the challenge of TM cell replacement therapy. Here, we demonstrate that mouse iPSCs derived from dermal fibroblasts can be induced to differentiate into TM-like cells, designated iPSC-TM, and demonstrate that these cells are similar morphologically and functionally to TM cells.
METHODS

Primary TM Cell Culture
Human eyes were procured through the Iowa Lions Eye Bank with the next of kin consent and processed within 8 hours post mortem. The anterior chamber was excised from the globe, and TM tissue was removed using a blunt dissection technique in which a 0.5-mm curette was used to separate a continuous strand of TM tissue away from the scleral spur, ciliary muscle, and Schwalbe's line. Trabecular meshwork cells were isolated from the tissue using collagenase digestion and cultured in ''human complete medium'' as reported by Stamer et al. 28 The tissue was rinsed twice with Dulbecco's modified Eagle's medium (DMEM) and digested for 2 hours at 378C in Dulbecco's phosphate-buffered saline (cation free, pH 7.4) containing 4 mg/mL collagenase-A (Worthington Biochemical Corp., Freehold, NJ, USA) and 4 mg/mL human serum albumin (Abcam, Cambridge, MA, USA). Following digestion, the cells were cultured in ''human complete medium'' containing 199E medium (Gibco, Grand Island, NY, USA), 20% fetal bovine serum (Gibco), 90 lg/mL porcine heparin (SigmaAldrich Corp., St. Louis, MO, USA), 20 U/mL Endothelial Cell Growth Supplement (Sigma-Aldrich Corp.), and 1.7 mM Lglutamine (Sigma-Aldrich Corp.) in six-well culture plates coated with 1% gelatin (Sigma-Aldrich Corp.). Cultures were maintained at 378C in 5% CO 2 in a humidified tissue culture incubator.
Preparation of iPSCs
Fibroblasts were cultured from 4-to 6-week-old transgenic mice constitutively expressing the reporter gene dsRed (B6.CgTg(ACTB-DsRed*MST)1Nagy/J (Jackson Laboratory, Bar Harbor, ME, USA). Induced PSCs were generated from dermal fibroblasts by lentiviral transduction of the four transcription factors Oct4, Sox2, Klf4, and c-Myc as previously described. 29 Five days after infection, cells were passaged onto a monolayer of inactive mouse embryonic fibroblasts and fed daily with pluripotency media containing DMEM F-12 medium (Gibco), 15% heat-inactivated fetal bovine serum (FBS; Lifeblood Medical, Inc., Freehold, NJ, USA), 0.0008% b-mercaptoethanol (Sigma-Aldrich Corp.), 1% 1003 nonessential amino acids (Gibco), 1 3 10 6 units/L leukemia inhibitory factor (LIF/ ESGRO; Millipore, Billerica, MA, USA), and 1% Primocin (Gibco). At 3 to 5 weeks post infection, iPSC colonies were picked, passaged, and clonally expanded for additional experimentation.
Differentiation of iPSCs
Mouse iPSCs were passaged onto feeder-free tissue culture plates coated with Matrigel (BD Biosciences, San Jose, CA, USA) and expanded in pluripotency media for 3 days prior to differentiation. Cells were then cocultured for up to 21 days beneath immortalized human TM cells (hTM5; a gift of Abe Clark 30 ) that were plated in cell culture inserts (Corning Inc., Corning, NY, USA). Cultures were fed daily with fresh media containing MEM-alpha (Gibco), 10% FBS (Gibco), and 1% Primocin (Gibco).
Immunohistochemistry
Induced PSC-TM were cultured on coverslips in six-well plates and harvested after 7, 14, or 21 days (D7, D14, and D21, respectively). Cells were rinsed with PBS and fixed in 4% paraformaldehyde for 20 minutes at room temperature. Sections were rinsed again in PBS, blocked with 1% bovine serum albumin (BSA), incubated with the primary antibody, and finally incubated with the corresponding secondary antibody. All sections were treated with 4 0 ,6-diamidino-2-phenylindole (DAPI) to facilitate orientation. Primary antibodies used were anti-caveolin 1 (Abcam), collagen 4 alpha 5 chain (Santa Cruz Biotechnology, Dallas, TX, USA), matrix protein Gla (Santa Cruz Biotechnology), myocilin (Abcam), tissue inhibitor of matrix metalloproteinase-3 (Thermo Pierce, Rockford, IL, USA), Vcam1 (R&D Systems, Minneapolis, MN, USA), Oct4 (Santa Cruz Biotechnology), Sox2 (R&D Systems), and Nanog (Abcam).
Secondary antibodies included donkey anti-rabbit Alexa 488, chicken anti-goat Alexa 488, and donkey anti-mouse Alexa 488 (Invitrogen, Carlsbad, CA, USA).
Phagocytosis Assay
Induced PSC-TM cells were grown in 12-well cell culture plates as described above and incubated with E. coliconjugated pHrodo green particles (0.5 mg/well; Invitrogen). Cells were investigated using epifluorescence microscopy. Fluorescence as a measure of ingested particles was measured using a Victor X3 multi plate reader (PerkinElmer, Waltham, MA, USA) every hour for up to 6 hours. Each data point represents the average of three independent experiments.
Proteomic Analyses
Induced PSC-TM, after removal of the inserts containing hTM5 cells, were exposed to dexamethasone (Dex, 100 nmol; Sigma-Aldrich Corp.) or phorbol 12-myristate acetate (TPA; 25 ng/mL; Sigma-Aldrich Corp.) for 72 hours. The cell culture media from untreated and treated cells were collected and albumin was removed using an albumin removal kit (Thermo Pierce). Protein concentrations were determined by measuring absorbance at 280 nm. Total protein (50 lg) was loaded on TGX 4-20% gels (Bio-Rad, Hercules, CA, USA). Proteins were transferred to polyvinylidene difluoride membrane at 100 V for 1 hour, blocked with 5% BSA at room temperature for 1 hour, and incubated with primary antibodies directed against either myocilin (Abcam) for Dex-treated cells or matrix metalloproteinase-3 (MMP3; Abcam) for TPA-treated cells. Immunoreactive bands were visualized using a horseradish peroxidase-conjugated secondary antibody and chemiluminescent detection. Images were captured on a Versadoc (Bio-Rad) imaging system, and band intensity was determined. Data were normalized to the detected level of tubulin content, and the ratio of myocilin and MMP3 before and after treatment was calculated. Each data point represents the results of three independent experiments.
RESULTS
Fibroblasts isolated from red fluorescent mice were harvested (Fig. 1A) , expanded, and transduced at a multiplicity of
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infection (MOI) of 5 with a lentiviral vector driving expression of the transcription factors Oct4, Sox2, Klf4, and c-Myc. At 3 to 5 weeks post transduction, iPSC colonies large enough for manual isolation (Fig. 1B) were picked and clonally expanded (Fig. 1C) . To demonstrate pluripotency, 2.5 3 10 6 undifferentiated cells were injected into immunecompromised mice. Four weeks post transplantation, tumors were resected, fixed, and sectioned. Histological analysis revealed teratomas containing tissue specific to each of the three embryonic germ layers, including ectoderm-derived neural rosettes (Fig. 1D, arrow) , mesoderm-derived bone (Fig. 1E, arrow) , and endoderm-derived glandular epithelium (Fig. 1F, arrow) .
In order to induce iPSCs to differentiate into TM-like cells, iPSCs were cocultured with the human cell line hTM5 30 for up to 21 days. This immortalized cell line was used here since it grows at a very consistent rate and displays minimal variation between passages. After approximately 7 days in coculture (D7), iPSCs started to differentiate and cells began to exhibit clear morphologic changes. Undifferentiated iPSC and TM cells were clearly distinguishable: iPSCs grew in colonies and were small round cells with small nuclei and little cytoplasm (asterisk in Figs. 2B, 2E) , while primary TM cells were more elongated and spindlelike and tended to grow apart from one another until confluency was reached (Fig. 2C) . Following 1 week in coculture, an increasing number of cells could be observed that had moved away from the original iPSC colonies and had assumed a cellular shape similar to that of primary TM cells (Fig. 2B) . However, initially, iPSC-TM representing intermediate stages could be frequently observed, for example, those possessing smaller nuclei than fully differentiated TM cells. Interestingly, the appearance of iPSC-TM was more reminiscent of primary TM cells than the hTM5 that served to induce their differentiation ( Fig. 2A) . Upon reaching confluency, the morphology of primary TM cells changed, and cells became more uniformly shaped (Fig. 2F ).
This appearance was also displayed by iPSC-TM cultures that reached confluency (Fig. 2E) . Furthermore, confluent iPSC-TM did not begin to form whorls or begin to grow in multiple layers, a behavior often observed with fibroblasts in culture.
To determine the ability of iPSC-TM to express specific TM proteins, we carried out immunohistochemistry using a series of antibodies directed against TM markers: caveolin (Cav1), 31 collagen IV (Col4A5), 32, 33 matrix Gla protein (MGP), 34, 35 myocilin (MYOC), 36 tissue inhibitor of metalloproteinases (TIMP3), 26, 37 and vascular cell adhesion molecule 1 (Vcam1). 38 We also carried out immunohistochemical analysis of markers of pluripotency, such as Nanog, Oct4, and Sox2. 29 Although differences in the rate of differentiation, cell growth, and nuclear expansion existed between individual cells, the immunofluorescent analysis demonstrates that many iPSC-TM began to express TM markers 7 days after the beginning of coculture (D7). All of the tested proteins were detectable after 14 or 21 days in coculture (D14 or D21, respectively) (Fig. 3) . In contrast, while initially all cells were positive for pluripotency markers, the fraction of positive cells decreased sharply over the culture period, although expression of these markers persisted in a fraction of cells until the end of the study period at D21. The labeling patterns resemble those observed in primary TM cells (Fig. A1, Appendix) .
Functionally, the ability to phagocytose and degrade material is an important feature of TM cells [39] [40] [41] [42] that is not observed in iPSCs. To further assess the development of a TM cell-like phenotype, we tested the ability of iPSC-TM to carry out phagocytosis after 7, 14, and 21 days in coculture. These data were compared to those derived from undifferentiated iPSCs. Here we used pHrodo bioparticles to measure phagocytosis activity in cell culture. The fluorescence of the particles increases dramatically at acidic pH. Under the conditions employed here, fluorescence is specifically emitted by particles that have been phagocytosed and transported to acidic intracellular compartments. As shown in Figure 4A , iPSCs differentiated for 10 days engulfed the particles, and intracellular fluorescence was readily observed while particles remaining outside the cells remained nonfluorescent.
The phagocytic activity of iPSC-TM can be quantitated in a cell culture system using a fluorescence-capable microplate reader. We measured developing fluorescence hourly for up to 6 hours after addition of the pHrodo bioparticles (Fig. 4B) . Undifferentiated iPSCs displayed low fluorescence throughout the entire period, indicating a very limited ability to carry out phagocytosis. However, coculture with TM cells for as few as 7 days significantly increased the ability of developing iPSC-TM to carry out this task (P ¼ 0.003 after 2 hours of incubation). Overall phagocytic ability of the iPSC-TM further significantly increased after 14 days in coculture (D7 versus D14 at 2 hours, P ¼ 0.22). Longer coculture only modestly enhanced the ability of iPSC-TM to take up the bioparticles, and the increase was no longer statistically significant when compared to earlier time points (D14 versus D21 at 2 hours, P ¼ 0.18). At all stages of differentiation, maximal readings were achieved 2 hours after addition of the bioparticles.
As an additional functional measure, we tested the ability of iPSC-TM to secret MMP3 or MYOC when treated with TPA or Dex, respectively. Both the TPA-induced formation of matrix metalloproteinases 43, 44 and the increased synthesis and secretion of MYOC in response to Dex [45] [46] [47] [48] are characteristic of TM cells, but are not observed in iPSCs. Western blot analysis of iPSC-TM conditioned media (Fig. 5) , collected after 3 days of exposure to either TPA or Dex, demonstrated a marked increase of MMP3 and MYOC similar to that observed in hTM5. In contrast, undifferentiated iPSCs displayed no changes in secretion of MMP3 or MYOC with or without treatment. These data demonstrate that iPSC-TM not only synthesize but also secrete both molecules at levels comparable to those observed in hTM5 cells.
DISCUSSION
Trabecular meshwork cells fulfill a vital role in retaining the structural integrity of the TM and in maintaining healthy levels of intraocular pressure. Loss and dysfunction of these cells are likely to contribute to the development of elevated IOP in POAG. In order to further study this cell type, and as a potential avenue toward cell-based glaucoma therapy, we sought to generate TM-like cells from iPSCs derived from fibroblasts. Herein, we present data to demonstrate that iPSCs can indeed be induced to assume a phenotype that resembles native TM cells in many important aspects.
Induced PSCs were generated using adult dsRed mouse dermal fibroblasts via retroviral induction of the transcription factors Oct4, Sox2, Klf4, and c-Myc as described previously. 29 These undifferentiated cells were clearly iPSCs as shown by a number of accepted criteria such as morphology and the ability to form teratomas.
Unfortunately, fewer specific markers and characteristic functional traits have been described that unequivocally identify TM cells. However, our approach to coculture iPSC with hTM5 cells induces clear morphological changes, and the resulting iPSC-TM resemble primary TM cells as reported by others. 28, 49 Actively dividing iPSC-TM assume an elongated spindle-like shape, but adopt a more compact shape once they have reached confluency. Remarkably, these cells resemble the morphology of primary cultured TM cells more closely than that of the hTM5 cells that serve to drive their differentiation. The reasons for this are unclear, but it is conceivable that the morphology of hTM5 is affected by immortalization and that this trait is not transmitted to newly generated iPSC-TM.
While a TM cell-specific marker has yet to be described, these cells do express a number of molecules that distinguish them from iPSCs and that, together, provide support that the derived iPSC-TM are very similar to cultured TM cells. Our data indicate that TM markers associated with endocytosis (e.g., Cav1 31 ) and extracellular matrix synthesis and degradation (e.g., Col4A5, 32, 33 Trabecular meshwork cells are known to be highly phagocytic, and it is thought that this ability plays an important role in the normal function of the conventional aqueous humor outflow pathway. [39] [40] [41] [42] The use of pHsensitive particles makes it possible to directly test phagocytotic function of iPSC-TM in comparison to iPSCs or hTM5. Our data demonstrate that iPSC-TM rapidly develop the ability to phagocytose material, although additional gains in phagocytic function are detected as iPSC-TM further mature. This increase either could be due to a larger capacity of each cell to take up material or may be the result of additional cells acquiring the ability to phagocytose. This question cannot be resolved using the current experimental design, but will be addressed in future studies.
Finally, we demonstrate that iPSC-TM respond to exposure to TPA and Dex with enhanced expression of MMP3 and MYOC, respectively, similar to the responses of primary TM cells described by others. [43] [44] [45] [46] [47] [48] While the significance of enhanced MYOC expression remains a matter of debate, MMP3 expression likely relates to turnover and maintenance of the extracellular matrix compartment of the TM and may have important ramifications for TM pliability. Taken together, our data demonstrate that iPSCs can be induced to assume a phenotype resembling that of native TM cells in many important aspects, morphologically and functionally. This process enables the establishment of iPSC-TM lines not only from mice but also from any consenting patient. Thus not only do iPSC-TM represent a valuable research tool, but also autologous transplantation into glaucomatous eyes with elevated IOP may ultimately help to restore function to the TM. This process could help to restore normal humor outflow, and thus it might be possible to permanently reinstate IOP control. 
